DK3615034T3 - Rucaparib, talazoparib, veliparib, olaparib og azd 2461 til behandling af forringet hudsårheling - Google Patents
Rucaparib, talazoparib, veliparib, olaparib og azd 2461 til behandling af forringet hudsårheling Download PDFInfo
- Publication number
- DK3615034T3 DK3615034T3 DK18721722.9T DK18721722T DK3615034T3 DK 3615034 T3 DK3615034 T3 DK 3615034T3 DK 18721722 T DK18721722 T DK 18721722T DK 3615034 T3 DK3615034 T3 DK 3615034T3
- Authority
- DK
- Denmark
- Prior art keywords
- talazoparib
- rucaparib
- veliparib
- olaparib
- azd
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17000743 | 2017-04-28 | ||
| PCT/EP2018/060435 WO2018197463A1 (en) | 2017-04-28 | 2018-04-24 | Rucaparib, talazoparib, veliparib, olaparib and azd 2461 for treating impaired skin wound healing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3615034T3 true DK3615034T3 (da) | 2021-08-23 |
Family
ID=58668702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18721722.9T DK3615034T3 (da) | 2017-04-28 | 2018-04-24 | Rucaparib, talazoparib, veliparib, olaparib og azd 2461 til behandling af forringet hudsårheling |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11638709B2 (da) |
| EP (1) | EP3615034B1 (da) |
| AU (1) | AU2018260096B2 (da) |
| CA (1) | CA3096136A1 (da) |
| DK (1) | DK3615034T3 (da) |
| WO (1) | WO2018197463A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220143011A1 (en) * | 2017-05-16 | 2022-05-12 | Bow River LLC | Methods of treatment with cyp3a4 substrate drugs |
| CN115485271A (zh) | 2020-04-28 | 2022-12-16 | 理森制药股份公司 | 用作聚(adp-核糖)聚合酶（parp）抑制剂的新型化合物 |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| CA3214298A1 (en) | 2021-04-08 | 2022-10-13 | Swaroop Kumar Venkata Satya VAKKALANKA | Inhibitors of poly(adp-ribose) polymerase |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| US20090263407A1 (en) * | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic Lipids and Uses Thereof |
| AU2018260094A1 (en) | 2017-04-28 | 2019-11-07 | Akribes Biomedical Gmbh | A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
-
2018
- 2018-04-24 AU AU2018260096A patent/AU2018260096B2/en active Active
- 2018-04-24 WO PCT/EP2018/060435 patent/WO2018197463A1/en active Application Filing
- 2018-04-24 US US16/607,611 patent/US11638709B2/en active Active
- 2018-04-24 DK DK18721722.9T patent/DK3615034T3/da active
- 2018-04-24 EP EP18721722.9A patent/EP3615034B1/en active Active
- 2018-04-24 CA CA3096136A patent/CA3096136A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018260096A1 (en) | 2019-11-07 |
| US20200078369A1 (en) | 2020-03-12 |
| EP3615034A1 (en) | 2020-03-04 |
| AU2018260096B2 (en) | 2023-08-24 |
| EP3615034B1 (en) | 2021-06-02 |
| CA3096136A1 (en) | 2018-11-01 |
| WO2018197463A1 (en) | 2018-11-01 |
| US11638709B2 (en) | 2023-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3658539T3 (da) | Forbindelser og sammensætninger til behandling af tilstande, som er forbundet med nlrp-aktivitet | |
| DK3600281T3 (da) | Kombinationsbehandling til behandling eller forebyggelse af tumorer | |
| DK3402499T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes | |
| DK3445388T3 (da) | Materialer og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
| DK3472455T3 (da) | Kontrol- eller behandlingssystem og fremgangsmåde | |
| DK3728121T3 (da) | Lanthaniddoterede, lagdelte dobbelthydroxider og fremgangsmåde til fremstilling af samme | |
| DK3640208T3 (da) | Molekularsi scm-14, syntesefremgangsmåde dertil og anvendelse deraf | |
| DK3640207T3 (da) | Molekularsi scm-15, syntesefremgangsmåde dertil og anvendelse deraf | |
| DK3615034T3 (da) | Rucaparib, talazoparib, veliparib, olaparib og azd 2461 til behandling af forringet hudsårheling | |
| DK3612579T3 (da) | Pultrudat, fremstilling og anvendelse heraf | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3532064T3 (da) | Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser | |
| DK3268374T3 (da) | Kv1.3-inhibitorer og deres medicinske anvendelse | |
| DK3653613T3 (da) | 1,3-disubstitueret ketenforbindelse og anvendelse deraf | |
| IL271728A (en) | Materials, uses and treatment methods | |
| DK3540102T3 (da) | Fremgangsmåde til garnspinding og/eller -snoning | |
| DK3458650T3 (da) | Fremgangsmåde til desinficering og vandhaneforbindelsesarrangement dertil | |
| DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi | |
| DK3691649T3 (da) | Sammensætninger og fremgangsmåder til sårbehandling | |
| CL2020000973A1 (es) | Composiciones y procedimientos para el tratamiento de linfoma difuso de celulas b grandes. | |
| DK3529234T3 (da) | Forbindelser, fremgangsmåde til opnåelse af forbindelserne, farmaceutisk sammensætning, anvendelse af forbindelserne og fremgangsmåde til behandling af psykiatriske lidelser og/eller søvnforstyrrelser | |
| DK3493812T3 (da) | Kombinationer af imetelstat og venetoclax til behandling af akut myeloid leukæmi | |
| DK3373922T3 (da) | Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri | |
| TWI800561B (zh) | 毛髮處理方法 |